Current Position:Activity > News > Insights
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Contact Information
If you have any more questions, please fill in the relevant information and we will reply to you as soon as possible to provide assistance!
Name
Contact Information
Email address
Reset
Submit
Current Position:Activity > News > Insights
Classification
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Contact Information
If you have any more questions, please fill in the relevant information and we will reply to you as soon as possible to provide assistance!
Name
Contact Information
Email address
Reset
Submit
Message consultation
reset
submit
Message
Message consultation
reset
submit